Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Results from a Phase I Study of Lapatinib with Gemcitabine and Cisplatin in Advanced or Metastatic Bladder Cancer: EORTC Trial 30061

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Intrahepatic Oxaliplatin and Systemic 5-FU +/- Cetuximab in Chemo-Naïve Patients with Liver Metastases from Colorectal Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Dual Inhibition of EGFR and VEGF in Heavily Pretreated Patients with Metastatic Colorectal Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Breast cancer in systemic lupus erythematosus

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Sexual Function and Quality of Life in a National Cohort of Survivors of Bilateral Testicular Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Luteinizing Hormone Receptor Is Expressed in Testicular Germ Cell Tumors: Possible Implications for Tumor Growth and Prognosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Mortality and admission to intensive care units after febrile neutropenia in patients with cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Prospective molecular and morphological assessment of testicular prepubertal-type teratomas in postpubertal men

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Use of antidepressants in women after prophylactic bilateral oophorectomy: A Danish national cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND/OBJECTIVE: Lapatinib is a potent HER1 and HER2 inhibitor. Gemcitabine-cisplatin (GC) is a standard chemotherapy regimen for advanced/metastatic bladder cancer. This phase I study examined the safety of lapatinib in combination with GC in patients with bladder cancer. The primary aim was to determine the maximum tolerated dose (MTD) of lapatinib in combination with GC.

METHODS: A 3 + 3 dose escalation protocol was used with lapatinib at 750, 1,000 and then 1,250 mg. It was dosed daily with gemcitabine (1,000 mg/m2 on days 1, 8 and 15) and cisplatin (70 mg/m2 on day 2) every 28 days. In all, 18 patients with a median age of 63 years (range 50-77) were included; 3/6, 3/5 and 6/7 patients received lapatinib at 750, 1,000 and 1,250 mg, combined with GC, in cohorts 1, 2 and 3, respectively.

RESULTS: No dose-limiting toxicities (DLTs) were observed in cohort 1 or 2 (3 patients each); in cohort 3 (2 × 3 patients), 1 of the 6 patients presented DLTs (grade 4, treatment-related febrile neutropenia and renal failure). Twelve patients received 6 cycles.

CONCLUSIONS: Lapatinib at 750-1,250 mg combined with GC appears safe and tolerable. The MTD of lapatinib combined with GC in bladder cancer was 1,250 mg.

OriginalsprogEngelsk
TidsskriftOncology
Vol/bind90
Udgave nummer1
Sider (fra-til)21-28
ISSN0030-2414
DOI
StatusUdgivet - 2016

ID: 46009060